United Therapeutics Eyes Billion-Dollar IPF Market—Can They Pull It Off?

United Therapeutics Corporation’s third-quarter results for 2025 demonstrate both the company’s operational strengths and challenges. United Therapeutics reported record revenues of $800 million, up 7% from the same period in 2024, largely driven by increased demand for Tyvaso and Orenitram, key therapies in their portfolio addressing pulmonary hypertension (PH) and interstitial lung diseases. This revenue growth is indicative of the effectiveness of their commercial strategies and market execution, underscoring the resilience of their business model despite increased competition. One of the highlights from the quarter was the positive clinical trial progress, particularly with three Phase III trials being fully enrolled, and strong results were released for pulmonary fibrosis. The results for this condition were reportedly the best ever, suggesting a significant impact. This reflects the company’s robust pipeline and their ability to expedite clinical developments, potentially expanding their impact on rare diseases.